Federico Hinestrosa
3PUBLICATIONS
24CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Mar 14, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.Raphael J Landovitz, Yvett Pinedo, Federico Hinestrosa
|Mar 13, 2025
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.Jürgen K Rockstroh, Roger Paredes, Pedro Cahn
|Oct 17, 2024
Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study.Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen
Pageof 1
Frequent Collaborators
1 joint publications
Charlotte-Paige Rolle
1 joint publications
Jürgen K Rockstroh
1 joint publications
Roger Paredes
1 joint publications
Pedro Cahn
1 joint publications
Simiso M Sokhela
1 joint publications
Sheetal Kassim
1 joint publications
Jade Ghosn
1 joint publications
Hiroyuki Gatanaga
1 joint publications
Ying Zhang
1 joint publications
Stephanie O Klopfer
